Converge Bio secured 25 million USD in Series A funding led by Bessemer Venture Partners to scale it...
The AMW Read
The article provides an incremental update on a new entrant in the Vertical AI—Healthcare/Bio segment via a Series A funding round.
NoveltySignificance
Healthcare & Bio · Player Map
Converge Bio secured 25 million USD in Series A funding led by Bessemer Venture Partners to scale its generative AI platform for biological data. Backed by Meta and OpenAI executives, the startup has achieved a 4.5x boost in protein yield across 40 active programs. By unifying DNA and protein modeling, they are resolving the R&D fragmentation that stalls pharma pipelines. This shift positions biological foundation models as the new core operating system for drug discovery. 🧬
